Biltmore Family Office’s Gilead Sciences GILD Stock Holding History

Biltmore Family Office’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,466	Closed	-$334K	–	181
2020 Q1	$334K	Sell	4,466 -1,898	-30%	-$131K	0.22%	105
2019 Q4	$414K	Buy	6,364 +1,555	+32%	+$101K	0.17%	116
2019 Q3	$305K	Sell	4,809 -638	-12%	-$41.7K	0.13%	126
2019 Q2	$368K	Sell	5,447 -629	-10%	-$41.4K	0.2%	98
2019 Q1	$395K	Buy	6,076 +220	+4%	+$14.6K	0.2%	102
2018 Q4	$366K	Buy	5,856 +1,531	+35%	+$107K	0.21%	101
2018 Q3	$334K	Hold	4,325	–	–	0.16%	116
2018 Q2	$306K	Hold	4,325	–	–	0.15%	114
2018 Q1	$326K	Buy	4,325 +325	+8%	+$25.8K	0.14%	128
2017 Q4	$287K	Buy	+4,000	New	+$304K	0.13%	129

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Biltmore Family Office's GILD Position: Q2 2020 in Review

Biltmore Family Office sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 4,466 shares — an estimated $334K sold.

Biltmore Family Office first reported a position in GILD in Q4 2017 and held it in 10 quarters. The position peaked at $414K in Q4 2019. 1,625 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

Biltmore Family Office reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
Biltmore Family Office sold 4,466 Gilead Sciences shares in Q2 2020, an estimated $334K.
Biltmore Family Office first reported a position in Gilead Sciences in Q4 2017 and held it in 10 quarters.
Biltmore Family Office's Gilead Sciences position peaked at $414K in Q4 2019.
1,625 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Biltmore Family Office's 13F filing for Q2 2020, filed 5 Aug 2020.